REFERENCES
1. Cantú JM, García-Cruz D, Sánchez-Corona J, Hernández A, Nazará Z. A distinct osteochondrodysplasia with hypertrichosis- Individualization of a probable autosomal recessive entity. Hum Genet 1982;60:36-41.
2. van Bon BW, Gilissen C, Grange DK, et al. Cantú syndrome is caused by mutations in ABCC9. Am J Hum Genet 2012;90:1094-101.
3. Harakalova M, van Harssel JJ, Terhal PA, et al. Dominant missense mutations in ABCC9 cause Cantú syndrome. Nat Genet 2012;44:793-6.
4. Grange DK, Roessler HI, McClenaghan C, et al. Cantú syndrome: findings from 74 patients in the international Cantú syndrome registry. Am J Med Genet C Semin Med Genet 2019;181:658-81.
5. Huang Y, McClenaghan C, Harter TM, et al. Cardiovascular consequences of KATP overactivity in Cantu syndrome. JCI Insight 2018;3:121153.
6. Singh GK, McClenaghan C, Aggarwal M, et al. A unique high-output cardiac hypertrophy phenotype arising from low systemic vascular resistance in Cantu syndrome. J Am Heart Assoc 2022;11:e027363.
7. McClenaghan C, Huang Y, Matkovich SJ, et al. The mechanism of high-output cardiac hypertrophy arising from potassium channel gain-of-function in Cantú syndrome. Function 2020;1:zqaa004.
8. Parrott A, Lombardo R, Brown N, Tretter JT, Riley L, Weaver KN. Cantu syndrome: a longitudinal review of vascular findings in three individuals. Am J Med Genet A 2020;182:1243-8.
9. McClenaghan C, Woo KV, Nichols CG. Pulmonary hypertension and ATP-sensitive potassium channels. Hypertension 2019;74:14-22.
10. Ma A, Gurnasinghani S, Kirk EP, et al. Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: initial experience. Am J Med Genet A 2019;179:1585-90.
11. Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017;38:1247-50.
12. Wang SW, Pohl JE, Rowlands DJ, Wade EG. Diazoxide in treatment of primary pulmonary hypertension. Br Heart J 1978;40:572-4.
13. Hall DR, Petch MC. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. Br Heart J 1987;58:420.
14. Chan NS, McLay J, Kenmure AC. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. Br Heart J 1987;57:207-9.
15. Patel N, The TG. New-onset neonatal pulmonary hypertension associated with a rhinovirus infection. Can Respir J 2012;19:33-4.
16. Pedraza-Bernal AM, Rodriguez-Martinez CE, Acuña-Cordero R. Predictors of severe disease in a hospitalized population of children with acute viral lower respiratory tract infections. J Med Virol 2016;88:754-9.
17. Houtman MJC, Chen X, Qile M, et al. Glibenclamide and HMR1098 normalize Cantú syndrome-associated gain-of-function currents. J Cell Mol Med 2019;23:4962-9.
18. McClenaghan C, Huang Y, Yan Z, et al. Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity. J Clin Invest 2020;130:1116-21.
19. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995;91:2028-35.
20. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998;32:297-304.
21. Allen BW, Stamler JS, Piantadosi CA. Hemoglobin, nitric oxide and molecular mechanisms of hypoxic vasodilation. Trends Mol Med 2009;15:452-60.
22. Pinto E Vairo F, Kemppainen JL, Vitek CRR, et al. Implementation of genomic medicine for rare disease in a tertiary healthcare system: mayo clinic program for rare and undiagnosed diseases (PRaUD). J Transl Med 2023;21:410.
23. Davis MJ, Kim HJ, Nichols CG. KATP channels in lymphatic function. Am J Physiol Cell Physiol 2022;323:C1018-35.
